Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Dennis SlamonOleg LipatovZbigniew NoweckiNicholas McAndrewBozena Kukielka-BudnyDaniil StroyakovskiyDenise A YardleyChiun-Sheng HuangPeter A FaschingJohn CrownAditya BardiaStephen ChiaSeock-Ah ImManuel Ruiz-BorregoSherene LoiBinghe XuSara HurvitzCarlos BarriosMichael UntchRebecca MorooseFrances ViscoKaren AfenjarRodrigo FrescoIrene SeverinYan JiFarhat GhaznawiZheng LiJuan P ZarateArunava ChakravarttyTetiana TaranGabriel N HortobagyiPublished in: The New England journal of medicine (2024)
Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer. (Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.).